AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
T   30.49 (+1.36%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
T   30.49 (+1.36%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
T   30.49 (+1.36%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
BABA   240.00 (+7.33%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
T   30.49 (+1.36%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:SWTXSpringWorks Therapeutics Stock Price, Forecast & News

$38.98
-1.57 (-3.87 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$38.56
Now: $38.98
$41.27
50-Day Range
$33.24
MA: $40.29
$47.75
52-Week Range
$17.02
Now: $38.98
$49.79
Volume3,122 shs
Average Volume305,028 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; and Nirogacestat + belantamab mafodotin, which is in Phase 1b clinical trials for the treatment of relapsed or refractory multiple myeloma. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trials in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions, which is in preclinical studies in a range of tumor models with BRAF mutations or fusions. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline plc to develop combination approaches with nirogacestat and mirdametinib, as well as other standalone medicines. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SWTX
CUSIPN/A
CIKN/A
Phone203-883-9490

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.49 per share

Profitability

Miscellaneous

Employees52
Market Cap$1.68 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive SWTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.

SpringWorks Therapeutics (NASDAQ:SWTX) Frequently Asked Questions

How has SpringWorks Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

SpringWorks Therapeutics' stock was trading at $33.23 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SWTX shares have increased by 17.3% and is now trading at $38.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SpringWorks Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SpringWorks Therapeutics.

When is SpringWorks Therapeutics' next earnings date?

SpringWorks Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for SpringWorks Therapeutics.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics (NASDAQ:SWTX) released its earnings results on Tuesday, May, 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. View SpringWorks Therapeutics' earnings history.

What price target have analysts set for SWTX?

6 equities research analysts have issued 1 year price objectives for SpringWorks Therapeutics' shares. Their forecasts range from $32.00 to $58.00. On average, they expect SpringWorks Therapeutics' stock price to reach $44.60 in the next year. This suggests a possible upside of 14.4% from the stock's current price. View analysts' price targets for SpringWorks Therapeutics.

Has SpringWorks Therapeutics been receiving favorable news coverage?

Media stories about SWTX stock have been trending negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. SpringWorks Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about SpringWorks Therapeutics.

Are investors shorting SpringWorks Therapeutics?

SpringWorks Therapeutics saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 1,650,000 shares, a drop of 9.3% from the May 31st total of 1,820,000 shares. Based on an average daily trading volume, of 149,500 shares, the short-interest ratio is presently 11.0 days. Approximately 5.9% of the company's shares are short sold. View SpringWorks Therapeutics' Current Options Chain.

Who are some of SpringWorks Therapeutics' key competitors?

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), BioXcel Therapeutics (BTAI), Aptevo Therapeutics (APVO), General Motors (GM), TapImmune (MRKR), Provention Bio (PRVB), Sitime (SITM), Albireo Pharma (ALBO) and Amarin (AMRN).

Who are SpringWorks Therapeutics' key executives?

SpringWorks Therapeutics' management team includes the following people:
  • Mr. Saqib Islam, CEO & Director (Age 49)
  • Dr. Jens Renstrup M.B.A., M.D., Chief Medical Officer (Age 54)
  • Dr. Badreddin Edris Ph.D., Chief Bus. Officer (Age 32)
  • Dr. Stephen P. Squinto, Acting Head of R&D and Director (Age 63)
  • Mr. Francis I. Perier Jr., Chief Financial Officer (Age 59)

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $38.98.

How big of a company is SpringWorks Therapeutics?

SpringWorks Therapeutics has a market capitalization of $1.68 billion. The company earns $-58,310,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis. SpringWorks Therapeutics employs 52 workers across the globe.

What is SpringWorks Therapeutics' official website?

The official website for SpringWorks Therapeutics is www.springworkstx.com.

How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company can be reached via phone at 203-883-9490 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.